AXIM Biotechnologies, Inc. (AXIM)
Oxford Ledge is still expanding full research coverage of AXIM. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
SEC filings
- 8-K 5.01; Departure/election of directors or officers 2024-10-15
- 10-Q Quarterly financial report (unaudited) 2024-08-19
- 10-Q/A Amended quarterly report 2024-05-22
- 10-Q Quarterly financial report (unaudited) 2024-05-20
- 10-K Annual financial report with audited statements 2024-04-16
Source: SEC EDGAR.
Annual results
4 years of annual figures for AXIM, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2023 | $39,518 | -$8.1M | -$0.04 |
| 2022 | $8,875 | -$6.2M | -$0.04 |
| 2021 | $60,460 | -$16.0M | $0.12 |
| 2018 | $195,614 | -$6.8M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for AXIM. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open AXIM in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.